Corbus Pharmaceuticals Holdings, Inc. reports clinical-stage drug-development news in oncology and obesity. Updates center on CRB-701, a next-generation Nectin-4 antibody-drug conjugate licensed from CSPC Megalith Biopharmaceutical, including data presentations in head and neck squamous cell carcinoma and cervical cancer, FDA interactions and Fast Track designations.
Company news also covers CRB-913, a peripherally restricted oral CB1 inverse agonist for obesity, and CRB-601, an anti-integrin monoclonal antibody targeting TGFβ activation. Recurring items include clinical trial disclosures, medical-meeting presentations, management conference appearances, governance changes and operating or financial results.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced CEO Yuval Cohen, Ph.D., will present at three upcoming virtual investor conferences. The events include the RBC Capital Markets Global Healthcare Conference on May 18, Oppenheimer Rare & Orphan Disease Summit on May 21, and the Jefferies Virtual Global Healthcare Conference on June 1. Each presentation will feature a fireside chat followed by a Q&A session. An audio webcast will be available on their website, with replays lasting 90 days. Corbus focuses on developing medicines that target the endocannabinoid system, with its lead candidate being lenabasum.
Corbus Pharmaceuticals Holdings announced the enrollment of the last participant in a Phase 2 study of lenabasum for treating systemic lupus erythematosus (SLE). This exploratory trial involves 101 participants and evaluates lenabasum's safety and efficacy alongside standard treatments over 16 weeks. The study is the first to target the cannabinoid receptor type 2 in SLE, with primary results expected in the second half of 2021. Lenabasum aims to provide an alternative to immunosuppressive treatments for inflammatory diseases.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced the completion of the final visit in the double-blind part of its Phase 3 DETERMINE study of lenabasum for treating dermatomyositis, a rare autoimmune disease. Topline data is expected in Q2 2021. The trial, involving 176 subjects, evaluates lenabasum's safety and efficacy against standard treatments. Lenabasum, granted Orphan Drug Designation by the FDA and EMA, aims to offer a safer alternative to current options. Dermatomyositis affects approximately 80,000 patients in North America, Europe, and Japan.
Corbus Pharmaceuticals (CRBP) announced progress in its clinical studies and a robust financial position with $127M cash on hand, expected to sustain operations into 2024. The Phase 3 DETERMINE study of lenabasum for dermatomyositis is on track for topline data in Q2 2021. While lenabasum did not meet primary endpoints in previous studies for systemic sclerosis and cystic fibrosis, the company is focusing on new drug development targeting metabolic diseases and cancer, with clinical studies anticipated in 2022.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) announced that CEO Yuval Cohen, Ph.D. will present at two virtual investor conferences. The 33rd Annual Virtual Roth Conference is scheduled for March 16, 2021 at 1:30 PM EST, followed by the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021 at 1:10 PM EST. Both events will include a fireside chat and Q&A session. Investors can access audio webcasts and replays on the Corbus website. Corbus develops innovative medicines targeting the endocannabinoid system, with its lead candidate, lenabasum, in trials for inflammatory diseases.
Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) will report its fourth quarter and year-end financial results on March 15, 2021, at 8:30 a.m. ET. The conference call will be led by CEO Yuval Cohen and will include the management team. Investors can join by dialing (877) 407-3978 for domestic or (412) 902-0039 for international access. A live webcast will also be available.
Corbus Pharmaceuticals (NASDAQ: CRBP) announced its participation in a webinar hosted by the New York Academy of Sciences on January 27, 2021. The event will feature presentations detailing the company's pipeline, including mechanistic studies of lenabasum, a CB2 agonist, and preclinical data from its oncology and metabolism programs. Key topics will include new insights into acute inflammation and the therapeutic potential of cannabinoid receptors. The presentations will be made by experts from the company and academia.
Corbus Pharmaceuticals announced that CEO Yuval Cohen will participate in a fireside chat at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 12:35 PM EST. This event will be accessible through a live audio webcast. Corbus is known for developing lenabasum, a treatment targeting the endocannabinoid system for chronic inflammatory diseases.
Corbus Pharmaceuticals (CRBP) announced plans to shorten its Phase 3 dermatomyositis trial from 52 to 28 weeks, projecting topline data by Q2 2021. This strategic move follows recent competitive pressures and extends the company's cash runway into Q2 2022. Financial results showed a net loss of $34.9 million for Q3 2020, up from $20.8 million year-over-year, with revenue decreasing to $1.2 million. Despite setbacks in the RESOLVE-1 systemic sclerosis and cystic fibrosis studies, Corbus remains committed to advancing its pipeline, including ongoing clinical trials for systemic lupus erythematosus.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) announced new data from the RESOLVE-1 Phase 3 study of lenabasum for systemic sclerosis. Post-hoc analyses revealed lenabasum treatment positively impacted lung function, particularly in patients on long-term immunosuppressant therapies. The study's results suggest lenabasum could meet a significant unmet need, presenting potential commercial opportunities. Systemic sclerosis affects up to 75,000 Americans, and lenabasum is recognized with Orphan Drug and Fast Track designations by the FDA.